As Lilly’s Realized Sales Prices Drop, Ricks Reiterates Criticism Of US Drug Price Plan
Executive Summary
With Lilly’s sales narrative hampered by global price pressures, Lilly CEO David Ricks again criticized drug price negotiation proposals before Congress. Mounjaro launch offers a bright spot, exceeding projections.
You may also be interested in...
Lilly Settles On Rolling Submission For Tirzepatide In Obesity
Plan for rolling submission means US FDA filing of GIP/GLP1 agonist in obesity could be complete by April 2023, setting up possibility of late 2023 approval.
US Pharmas Display Defensive Mettle But Headwinds Mount
US big pharma manufacturers generally delivered sales and earnings growth in the second quarter and reaffirmed guidance despite currency headwinds; US drug pricing legislation could present a tipping pressure point.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: what Amgen’s $3.7bn ChemoCentryx buy means; Lilly’s CEO on US drug pricing legislation; Pfizer’s GBT acquisition; new data for Amgen’s KRAS inhibitor combo; and a major China ADC alliance for Sanofi.